Skip to main content

B8011011 A Phase 1b/2 Open Label Umbrella Study of Sasanlimab Combined with Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants with Non-Small Cell Lung Cancer (NSCLC)

NCT04585815

A Phase 1b/2 Open Label Umbrella Study of Sasanlimab Combined with Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants with Non-Small Cell Lung Cancer (NSCLC)

Associated Conditions

Lung Cancer

Principal Investigator

Sponsor

Pfizer

You are being asked to take part in this study because you have non-small cell lung cancer and your cancer has a change (mutation) in a agene responsible for producing a protein called BRAF. This mutation can cause uncontrolled growth in your tumor. The purpose of this study is to learn about the effects of the study drugs, sasanlimab, encorafenib, and binimetinib, when given as a combination treatment for your type of lung cancer.

This study is currently enrolling.